Patent · US Active

Pancreatic islets of transgenic LEA29Y animals for treating diabetes

US10286013B2 · kind B2 · utility

0Cited by

1References

16Claims

0Family size

Assignee

MWM BIOMODELS GMBH · DE

Inventors

Eckhard Wolf · Reichenbach/Oberlausitz, DE
Nikolai Klymiuk · Hohenkammer, DE
Lelia Wolf-Van Buerck · Aschheim, DE
Jochen Seißler · Hersbruck, DE

Key dates

Filing date	Oct 27, 2016
Grant date	May 14, 2019
Priority date	—
Expiry date	Oct 27, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to methods of treating diabetes in a human subject comprising the use of pancreatic islets or of embryonic pancreatic tissue of a transgenic animal, wherein said transgenic animal contains a polynucleotide sequence encoding a CTLA4 peptide-immunoglobulin fusion, preferably LEA29Y, and expresses said CTLA4 peptide-immunoglobulin fusion in a tissue-specific manner in pancreatic islets.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.